Hierarchical	O
Targeting	O
Strategy	B:C0035171
for	O
Enhanced	O
Tumor	O
Tissue	I:C0475358
Accumulation	O
/	O
Retention	O
and	O
Cellular	O
Internalization	I:C0014139
Targeted	O
delivery	O
of	O
therapeutic	O
agents	I:C1611640
is	O
an	O
important	O
way	O
to	O
improve	O
the	O
therapeutic	O
index	O
and	O
reduce	O
side	O
effects	I:C0041755
.	O

Hierarchical	O
Targeting	O
Strategy	O
for	O
Enhanced	O
Tumor	B:C0475358
Tissue	I:C0475358
Accumulation	O
/	O
Retention	O
and	O
Cellular	O
Internalization	I:C0014139
Targeted	O
delivery	O
of	O
therapeutic	O
agents	I:C1611640
is	O
an	O
important	O
way	O
to	O
improve	O
the	O
therapeutic	O
index	O
and	O
reduce	O
side	O
effects	I:C0041755
.	O

Hierarchical	O
Targeting	O
Strategy	O
for	O
Enhanced	O
Tumor	O
Tissue	I:C0475358
Accumulation	O
/	O
Retention	O
and	O
Cellular	B:C0014139
Internalization	I:C0014139
Targeted	O
delivery	O
of	O
therapeutic	O
agents	I:C1611640
is	O
an	O
important	O
way	O
to	O
improve	O
the	O
therapeutic	O
index	O
and	O
reduce	O
side	O
effects	I:C0041755
.	O

Hierarchical	O
Targeting	O
Strategy	O
for	O
Enhanced	O
Tumor	O
Tissue	I:C0475358
Accumulation	O
/	O
Retention	O
and	O
Cellular	O
Internalization	I:C0014139
Targeted	O
delivery	O
of	O
therapeutic	B:C1611640
agents	I:C1611640
is	O
an	O
important	O
way	O
to	O
improve	O
the	O
therapeutic	O
index	O
and	O
reduce	O
side	O
effects	I:C0041755
.	O

Hierarchical	O
Targeting	O
Strategy	O
for	O
Enhanced	O
Tumor	O
Tissue	I:C0475358
Accumulation	O
/	O
Retention	O
and	O
Cellular	O
Internalization	I:C0014139
Targeted	O
delivery	O
of	O
therapeutic	O
agents	I:C1611640
is	O
an	O
important	O
way	O
to	O
improve	O
the	O
therapeutic	O
index	O
and	O
reduce	O
side	B:C0041755
effects	I:C0041755
.	O

To	O
design	O
nanoparticles	O
for	O
targeted	O
delivery	O
,	O
both	O
enhanced	O
tumor	B:C0475358
tissue	I:C0475358
accumulation	O
/	O
retention	O
and	O
enhanced	O
cellular	O
internalization	I:C0014139
should	O
be	O
considered	O
simultaneously	O
.	O

To	O
design	O
nanoparticles	O
for	O
targeted	O
delivery	O
,	O
both	O
enhanced	O
tumor	O
tissue	I:C0475358
accumulation	O
/	O
retention	O
and	O
enhanced	O
cellular	B:C0014139
internalization	I:C0014139
should	O
be	O
considered	O
simultaneously	O
.	O

So	O
far	O
,	O
there	O
have	O
been	O
very	O
few	O
nanoparticles	O
with	O
immutable	O
structures	B:C0678594
that	O
can	O
achieve	O
this	O
goal	O
efficiently	O
.	O

Hierarchical	O
targeting	O
,	O
a	O
novel	O
targeting	O
strategy	B:C0035171
based	O
on	O
stimuli	O
responsiveness	O
,	O
shows	O
good	O
potential	O
to	O
enhance	O
both	O
tumor	O
tissue	I:C0475358
accumulation	O
/	O
retention	O
and	O
cellular	O
internalization	I:C0014139
.	O

Hierarchical	O
targeting	O
,	O
a	O
novel	O
targeting	O
strategy	O
based	O
on	O
stimuli	O
responsiveness	O
,	O
shows	O
good	O
potential	O
to	O
enhance	O
both	O
tumor	B:C0475358
tissue	I:C0475358
accumulation	O
/	O
retention	O
and	O
cellular	O
internalization	I:C0014139
.	O

Hierarchical	O
targeting	O
,	O
a	O
novel	O
targeting	O
strategy	O
based	O
on	O
stimuli	O
responsiveness	O
,	O
shows	O
good	O
potential	O
to	O
enhance	O
both	O
tumor	O
tissue	I:C0475358
accumulation	O
/	O
retention	O
and	O
cellular	B:C0014139
internalization	I:C0014139
.	O

Here	O
,	O
the	O
recent	O
design	O
and	O
development	O
of	O
hierarchical	O
targeting	O
nanoplatforms	O
,	O
based	O
on	O
changeable	O
particle	O
sizes	O
,	O
switchable	O
surface	O
charges	O
and	O
activatable	O
surface	B:C0205148
ligands	O
,	O
will	O
be	O
introduced	O
.	O

Here	O
,	O
the	O
recent	O
design	O
and	O
development	O
of	O
hierarchical	O
targeting	O
nanoplatforms	O
,	O
based	O
on	O
changeable	O
particle	O
sizes	O
,	O
switchable	O
surface	O
charges	O
and	O
activatable	O
surface	O
ligands	B:C0023688
,	O
will	O
be	O
introduced	O
.	O

In	O
general	O
,	O
the	O
targeting	O
moieties	O
in	O
these	O
nanoplatforms	O
are	O
not	O
activated	O
during	O
blood	B:C0005775
circulation	I:C0005775
for	O
efficient	O
tumor	O
tissue	I:C0475358
accumulation	O
,	O
but	O
re-activated	O
by	O
certain	O
internal	O
or	O
external	O
stimuli	O
in	O
the	O
tumor	O
microenvironment	O
for	O
enhanced	O
cellular	O
internalization	I:C0014139
.	O

In	O
general	O
,	O
the	O
targeting	O
moieties	O
in	O
these	O
nanoplatforms	O
are	O
not	O
activated	O
during	O
blood	O
circulation	I:C0005775
for	O
efficient	O
tumor	B:C0475358
tissue	I:C0475358
accumulation	O
,	O
but	O
re-activated	O
by	O
certain	O
internal	O
or	O
external	O
stimuli	O
in	O
the	O
tumor	O
microenvironment	O
for	O
enhanced	O
cellular	O
internalization	I:C0014139
.	O

In	O
general	O
,	O
the	O
targeting	O
moieties	O
in	O
these	O
nanoplatforms	O
are	O
not	O
activated	O
during	O
blood	O
circulation	I:C0005775
for	O
efficient	O
tumor	O
tissue	I:C0475358
accumulation	O
,	O
but	O
re-activated	O
by	O
certain	O
internal	B:C0205102
or	O
external	O
stimuli	O
in	O
the	O
tumor	O
microenvironment	O
for	O
enhanced	O
cellular	O
internalization	I:C0014139
.	O

In	O
general	O
,	O
the	O
targeting	O
moieties	O
in	O
these	O
nanoplatforms	O
are	O
not	O
activated	O
during	O
blood	O
circulation	I:C0005775
for	O
efficient	O
tumor	O
tissue	I:C0475358
accumulation	O
,	O
but	O
re-activated	O
by	O
certain	O
internal	O
or	O
external	B:C0205101
stimuli	O
in	O
the	O
tumor	O
microenvironment	O
for	O
enhanced	O
cellular	O
internalization	I:C0014139
.	O

In	O
general	O
,	O
the	O
targeting	O
moieties	O
in	O
these	O
nanoplatforms	O
are	O
not	O
activated	O
during	O
blood	O
circulation	I:C0005775
for	O
efficient	O
tumor	O
tissue	I:C0475358
accumulation	O
,	O
but	O
re-activated	O
by	O
certain	O
internal	O
or	O
external	O
stimuli	O
in	O
the	O
tumor	O
microenvironment	O
for	O
enhanced	O
cellular	B:C0014139
internalization	I:C0014139
.	O

